Health Law



Meet the Co-chairs - TAGLAW


Burkett, Teresa Meinders
Conner & Winters, LLP
tburkett@cwlaw.com


Health Law


Introduction of the public-private partnership (“PPP”) method in the healthcare sector in Turkey has already significantly affected growth of the healthcare sector in the last few years, and new wave of PPP projects over the next five years is expected to be the main driver of expansion in the healthcare services sector[1]. In healthcare PPP projects, the project companies undertake the implementation of the health campus PPP project by executing a private law implementation agreement (i.e., the project agreement) with the Ministry of Health (“MoH”), and the MoH agrees to make certain payments in return. Such payments are used for the repayment of the loans obtained for the project and expenditures of the projects.

Read more: Healthcare PPP Projects: Payment Capacity of the Turkish Ministry of Health


By: Jeremy A. Ball, Matthew M. Cobb and Ruth Levy

Donald Trump’s victory in the presidential election combined with Republicans maintaining control of both chambers of Congress has the potential to alter the health care landscape significantly. While little is certain in politics, President-elect Trump and Congressional Republicans have campaigned and pledged for health care reform to include the repeal and replacement of the Affordable Care Act (ACA).

Read more: Recent Elections Will Bring Changes to Health Care


Contact: David Black

Last night the Florida Right to Medical Marijuana Initiative, Amendment 2, received 71 percent approval, far more than the 60 percent required for passage. The passage of Amendment 2 will expand the marijuana industry in Florida – currently dominated by the 2014 Compassionate Medical Cannabis Act, commonly known as Florida’s “Charlotte’s Web” law – opening the floodgates to what is expected to be a lucrative $1.5 billion industry by 2020.

Read more: Medical Marijuana in Florida: Amendment 2’s Passage


In a much anticipated decision, the Federal Court last week found in favour of a manufacturer of generic veterinary products in its action against the Australian Pesticides and Veterinary Medicines Authority (APVMA). Partner, Dr Teresa Nicoletti and Lawyer, Sebastian Tonkin discuss this decision further.

Read more: Australia Federal Court finds against APVMA on confidential commercial information


By: Ferdausur Rahman, Partner, A.S & Associates

Establishment of large pharmaceutical industries has increased since the liberation of Bangladesh. During the initial period, the industries aimed at meeting the in-coutry demand of products; however, with time and globalization, the industries started exploring opportunities for expanding their market outside of the country. Generally, the national industries were producing generic drugs and they usually have weak Research and Development activities. The situation is gradually changing and the industries are increasingly recognizing that without quality control to meet international standards, their efforts to export even the generic product will not be successful. This highlights the importance of establishing Clinical Research Organizations (CRO) in Bangladesh to develop capacity to conduct bioequivalence studies that meet international standards, more importantly FDA and European requirements. Additionally, some of the industries have started producing vaccines, which will necessitate development of further capacity of the pharmaceutical industry as well.

Download the entire article.